Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Using Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)

NCT01192555 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT01192555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01192555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Using Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 30, 2010
Completion date
June 30, 2027
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma